"Enzymatica’s sales in Germany were halted in 2018 as the regional court put restrictions on the marketing of the mouth spray ViruProtect. Unlike ViruProtect, the new mouth spray will be marketed as a cosmetic product rather than a medical device. The new product is based on the same barrier technology as previous products from Enzymatica under a different brand, but the marketing potential in terms of ‘claims’ will be limited as the new product will be marketed under the cosmetics directive."
Länk till uppdragsanalys nedan.